Development of a multicellular pancreatic tumor microenvironment system using patient-derived tumor cells

The development of drugs to treat cancer is hampered by the inefficiency of translating pre-clinical in vitro monoculture and mouse studies into clinical benefit. There is a critical need to improve the accuracy of evaluating pre-clinical drug efficacy through the development of more physiologically...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Lab on a chip Ročník 19; číslo 7; s. 1193
Hlavní autori: Gioeli, Daniel, Snow, Chelsi J, Simmers, Michael B, Hoang, Stephen A, Figler, Robert A, Allende, J Ashe, Roller, Devin G, Parsons, J Thomas, Wulfkuhle, Julia D, Petricoin, Emanuel F, Bauer, Todd W, Wamhoff, Brian R
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: England 27.03.2019
Predmet:
Biomimetics - methods
Carcinoma, Pancreatic Ductal - pathology
Cell Proliferation - drug effects
Humans
Tumor Microenvironment - drug effects
ISSN:1473-0189, 1473-0189
On-line prístup:Zistit podrobnosti o prístupe
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:The development of drugs to treat cancer is hampered by the inefficiency of translating pre-clinical in vitro monoculture and mouse studies into clinical benefit. There is a critical need to improve the accuracy of evaluating pre-clinical drug efficacy through the development of more physiologically relevant models. In this study, a human triculture 3D in vitro tumor microenvironment system (TMES) was engineered to accurately mimic the tumor microenvironment. The TMES recapitulates tumor hemodynamics and biological transport with co-cultured human microvascular endothelial cells, pancreatic ductal adenocarcinoma, and pancreatic stellate cells. We demonstrate that significant tumor cell transcriptomic changes occur in the TMES that correlate with the in vivo xenograft and patient transcriptome. Treatment with therapeutically relevant doses of chemotherapeutics yields responses paralleling the patients' clinical responses. Thus, this model provides a unique platform to rigorously evaluate novel therapies and is amenable to using patient tumor material directly, with applicability for patient avatars.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1473-0189
1473-0189
DOI:10.1039/c8lc00755a